XLV Was Trading Higher after Paying Dividends
The Health Care Select Sector ETF (XLV) rose by 1.1% and closed at $72.38 on December 23. XLV is trading well above its 20-day, 50-day, and 100-day moving averages.
Parsing the Baxalta–Shire Material Adverse Effect Clause, Part 1
The standard MAE clause basically says that anything bad that happens to Baxalta and delays or ruins the economics of the deal is a MAE, with some exceptions.
Biogen’s Hemophilia Drugs Continue to Capture Market Share in 1Q16
Biogen’s hemophilia drugs, Alprolix and Eloctate, continued to capture market share in 1Q16.
How Did Novo’s 2 Segments Perform in 1Q16?
Novo Nordisk’s two business segments are diabetes and obesity care and biopharmaceuticals. In 1Q16, they saw annual sales growth of 6% and 15%, respectively.
Could Baxalta Maintain Its Leadership in the Hemophilia Space?
Baxalta’s (BXLT) hemophilia portfolio comprises of Advate, Adynovate, Rixubis, Recombinate, Hemofil M, Immunate, Immunine, and Prothromplex Total.
What Are the Current Treatment Options for Hemophilia?
Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.
BMN 270: A Big Valuation Catalyst for BioMarin
On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.
Baxalta Rose on FDA’s Approval of Vonvendi
Baxalta (BXLT) rose by 0.7% on December 9, 2015. The stock moved up as the FDA (US Food and Drug Administration) approved its drug Vonvendi.
Interpreting Baxter’s Recent Dividend Announcement
On November 14, 2017, Baxter International (BAX) announced a quarterly dividend of $0.16 per share, payable on January 2, 2018.
A Promising Uptake for Vertex’s Orkambi
It’s been nine months since Vertex Pharmaceuticals (VRTX) launched Orkambi. Out of the 8,500 eligible patients, around 5,500 are using the drug.
After Spinning Off Hemophilia Business, What’s Next for Biogen?
Biogen (BIIB) announced the spin-off of its hemophilia business on May 3, 2016.
BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%
As of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI).
Shire’s Shareholders Approve Baxalta Merger: What’s Next?
Shire (SHPG) performed the worst among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) on May 27, 2016.
What Does the Future Hold for Oncaspar?
Baxalta’s (BXLT) oncology portfolio came into existence in 2015 after the company’s acquisition of Oncaspar.
How Is Baxalta Leading the Hematology Space?
Baxalta’s (BXLT) hematology segment includes hemophilia and inhibitor therapies.
Baxalta: How Is Its Immunology Portfolio Performing?
Baxalta’s (BXLT) immunology drugs comprise immunoglobulin therapies and biotherapeutics.
Could Gene Therapy Be a Next-Generation Treatment for Hemophilia?
Gene therapy is the emerging platform for hemophilia care. If approved, it would be a paradigm.
A Look at Baxalta’s Product Segments
Baxalta’s (BXLT) product portfolio can be divided into three parts: hematology, immunology, and oncology.
The Shire-Baxalta Merger: A Look at the Details
Following news of the Shire-Baxalta merger, Baxalta’s share price rose and Shire’s share price fell.
Baxalta: Growth through Acquisitions
In March 2013, Baxalta acquired Inspiration BioPharmaceuticals. Through this acquisition, it gained the investigational drug Obizur and related assets.
XLV Mid-Cap Stocks: Why Mallinckrodt Fell Due to Profit-Booking
Mallinckrodt (MNK) fell by 4.5% due to profit-booking. It closed at $58.40. The stock remained volatile on the backdrop of Valeant’s (VRX) episode.
Allergan Fell on the Possible Termination of Pfizer Merger
The Dow Jones Industrial Average went down by 0.75% on April 5, 2016, as the US markets followed the global sell-off trend.
XBI Large-Cap News: Amid Beatdowns, Regeneron Has an Announcement
All 11 large-cap stocks that XBI holds in its portfolio declined on March 23. Large-cap stocks account for 19.3% of XBI’s portfolio.
How Baxter’s Biosciences Spin-off into Baxalta Improved Its Valuation
On July 1, 2015, Baxter separated its Biosciences division into a new entity named Baxalta in an effort to divest risky segments and streamline operations.
Demand for Hemophilia Drugs Could Grow Biogen’s Revenue in 2016
In 2016, Biogen (BIIB) expects strong growth in demand for Eloctate, its hemophilia drug. Eloctate is expected to be adopted by more hemophilia patients who require long-acting therapies.
The Baxalta–Shire merger: Basics of Shire Pharmaceuticals
Shire is a biopharmaceutical company that focuses on rare diseases. Shire is best known for its treatments in ADHD, and the market here is quite large.
Growth and Synergies Drive the Baxalta–Shire Merger
The Baxalta–Shire merger could create the top platform for rare diseases in the world. Baxalta brings Advate, a treatment for hemophilia, a rare blood disease.
Shire Seals the Deal with Baxalta after a Long Negotiation
On Monday, January 11, 2016, Shire agreed to buy Baxalta for a combination of cash and stock. BXLT shareholders will receive $18.0 cash per share of BXLT.
US Stock Indexes Fell in December amid Falling Oil Prices
Let’s see why US stock indexes fell. The three US equity indexes that we review in this December recap series fell from November 30 to December 31, 2015.